2026-07-23T18:45:34Zhttps://repisalud.isciii.es/rest/oai/request
oai:repisalud.isciii.es:20.500.12105/226832024-11-29T03:32:44Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967
Repisalud author Llor, Carl author Perez, Almudena author Carandell Jöger, Eugenia author Garcia-Sangenis, Anna author Rezola Gamboa, Javier author Llorente, Marian author Gestoso, Salvador author Bobe, Francesc author Roman-Rodriguez, Miguel author Cots, Josep M author Hernandez, Silvia author Cortes, Jordi author Miravitlles, Marc author Morros, Rosa 2024-09-10T13:07:03Z 2024-09-10T13:07:03Z 2019-01 Llor C, Perez A, Carandell E, Garcia-Sangenis A, Rezola J, Llorente M, et al. Efficacy of high doses of penicillin versus amoxicillin in the treatment of uncomplicated community acquired pneumonia in adults. A non-inferiority controlled clinical trial. Aten Prim. 2019 Jan;51(1):32-9. Epub 2017 Oct 20. 10.1016/j.aprim.2017.08.003 1578-1275 0212-6567 Atencion Primaria http://hdl.handle.net/20.500.13003/17270 29061311 L618847810 2-s2.0-85031741714 https://hdl.handle.net/20.500.12105/22683 455491200006 Introduction: Community-acquired pneumonia (CAP) is treated with penicillin in some northern European countries. Objectives: To evaluate whether high-dose penicillin V is as effective as high-dose amoxicillin for the treatment of non-severe CAR. Design: Multicentre, parallel, double-blind, controlled, randomized clinical trial. Setting: 31 primary care centers in Spain. Participants: Patients from 18 to 75 years of age with no significant associated comorbidity and with symptoms of lower respiratory tract infection and radiological confirmation of CAP were randomized to receive either penicillin V 1.6 million units, or amoxicillin 1000 mg three times per day for 10 days. Main measurements: The main outcome was clinical cure at 14 days, and the primary hypothesis was that penicillin V would be non-inferior to amoxicillin with regard to this outcome, with a margin of 15% for the difference in proportions. EudraCT register 2012-003511-63. Results: A total of 43 subjects (amoxicillin: 28; penicillin: 15) were randomized. Clinical cure was observed in 10 (90.9%) patients assigned to penicillin and in 25 (100%) patients assigned to amoxicillin with a difference of -9.1% (95% CI, -41.3% to 6.4%; p=.951) for non-inferiority. In the intention-to-treat analysis, amoxicillin was found to be 28.6% superior to penicillin (95% CI, 7.3-58.1%; p =.009 for superiority). The number of adverse events was similar in both groups. Conclusions: There was a trend favoring high-dose amoxicillin versus high-dose penicillin in adults with uncomplicated CAR The main limitation of this trial was the low statistical power due to the low number of patients included. eng Community-acquired pneumonia Randomized controlled trial Penicillin Amoxicillin Adults Efficacy of high doses of penicillin versus amoxicillin in the treatment of uncomplicated community acquired pneumonia in adults. A non-inferiority controlled clinical trial research article